Skip to content

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer

Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01084785
Acronym
Biobank
Enrollment
10000
Registered
2010-03-11
Start date
2003-01-01
Completion date
2026-05-01
Last updated
2025-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer, genomics, proteomics

Brief summary

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.

Detailed description

It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.

Interventions

None listed

Sponsors

Maastricht University Medical Center
CollaboratorOTHER
Maastricht Radiation Oncology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* cancer

Exclusion criteria

* not able to comply with follow-up

Countries

Netherlands

Contacts

Primary ContactPhilippe Lambin, Prof PHD
philippe.lambin@maastro.nl31 (0) 088 44 55 666
Backup ContactDirk De Ruysscher, Prof PHD
dirk.deruysscher@maastro.nl31 (0) 088 44 55 666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026